Overview
Theravance Biopharma, Inc. (NASDAQ:TBPH) saw its shares decline 29% on Tuesday following the company announcement that its Phase 3 CYPRESS trial of ampreloxetine for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy failed to meet the study's primary endpoint. The company said the trial did not demonstrate statistical significance in the change in the Orthostatic Hypotension Symptom Assessment composite score at Week 8 during the double-blind randomized withdrawal period.
Trial results and program decision
According to the company, secondary endpoints showed similar trends to the primary outcome. In light of the results, Theravance Biopharma has decided to wind down its ampreloxetine development program.
Strategic Review and potential sale
Theravance said its Strategic Review Committee is accelerating an evaluation of alternatives intended to maximize shareholder value. The review may include a potential sale of the company. The Committee has been working with Lazard, its independent financial advisor, since the Committee's formation in 2024.
Cost reductions and organizational changes
The company announced an organizational restructuring designed to reduce its cost base by about 60%, or roughly $70 million, relative to 2025 preliminary actuals of approximately $110 million. The restructuring is expected to affect about 50% of the overall workforce and will include winding down the research and development function and a significant reduction in general and administrative functions.
Theravance projects that full run-rate cost savings will be realized in the third quarter of 2026. Beginning in that quarter the company expects to generate approximately $60 million to $70 million of annualized cash flow. That projection includes an estimated $45 million to $55 million of Income from Operations and amounts from Interest and Other Income, and it excludes any potential income from the $100 million TRELEGY milestone.
Cash position and product sales
The company reported cash of $326.5 million as of December 31, 2025, with no debt on the balance sheet. Theravance expects to hold approximately $400 million in cash at the end of the first quarter of 2026, reflecting receipt of 2025 milestones.
Theravance also reported that YUPELRI, its nebulized bronchodilator for chronic obstructive pulmonary disease, posted annual U.S. net sales of $266.6 million in fiscal 2025, an increase of 12% year-over-year.
Outlook and immediate implications
The company is taking a two-pronged approach in response to the trial outcome: halt investment in the failed therapy and reduce operating costs materially while accelerating strategic options work. Specific timelines include achieving full run-rate savings by Q3 2026 and realizing the projected annualized cash flow beginning in that quarter.
What remains uncertain
Details remain limited with respect to the timing and execution of any potential transaction resulting from the Strategic Review Committee's work. Additionally, the full operational impact of winding down R&D and halving the workforce will depend on further implementation steps that Theravance has not laid out in detail.
Financial and operational figures cited in this article are those provided by the company and reflect the company's own disclosures.